Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide

LTS occurs in select patients who achieve a CR to chemotherapy. However, this occurs in only a minority of patients and, in most cases, the longer survival is likely the result of indolent disease biology or host factors.